Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pfizer Inc. is conducting a Phase 3 clinical study titled ‘Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age.' The study aims to evaluate the long-term safety of rimegepant, a drug intended for the acute treatment of migraines in young patients. This research is significant as it could lead to new treatment options for pediatric migraine sufferers.
The intervention being tested is rimegepant, an oral disintegrating tablet (ODT) available in doses of 75 mg, 50 mg, or 35 mg. It is designed to provide relief from migraine symptoms quickly and effectively.
The study is interventional with a single-group assignment model, meaning all participants receive the same treatment. There is no masking, so both researchers and participants know the treatment being administered. The primary purpose of the study is treatment-focused, aiming to gather data on the drug’s safety and efficacy.
The study began on February 4, 2021, and is currently recruiting participants. The last update was submitted on October 20, 2025, indicating ongoing progress. These dates are crucial for tracking the study’s timeline and assessing its development stage.
For investors, this study could have significant market implications. If successful, rimegepant could enhance Pfizer’s portfolio, potentially boosting its stock performance and investor confidence. The study’s progress is particularly relevant in the competitive pharmaceutical industry, where advancements in migraine treatment are highly sought after.
The study is ongoing, with further details available on the ClinicalTrials portal.